No products in the cart.
Pre-made Secukinumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-510
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Secukinumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Secukinumab, sold under the brand name Cosentyx, is a human IgG1¦Ê monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A.
| Products Name (INN Index) | Pre-Made Secukinumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody |
|---|---|
| INN Name | Secukinumab |
| Target | IL17A |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 6wio:AB/6wir:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Beth Israel Deaconess Medical Center,GWT-TUD GmbH,Icahn School of Medicine at Mount Sinai,Novartis,Alcon |
| Conditions Approved | Ankylosing spondylitis,Plaque psoriasis,Psoriatic arthritis,Pustular psoriasis |
| Conditions Active | Hidradenitis suppurativa,Juvenile rheumatoid arthritis,Non-radiographic axial spondyloarthritis,Rheumatoid arthritis,Alopecia areata,Atopic dermatitis,Giant cell arteritis,Necrobiosis lipoidica,Tendo |
| Conditions Discontinued | Asthma,Crohn's disease,Dry eyes,Multiple sclerosis,Polymyalgia rheumatica,Type 1 diabetes mellitus,Uveitis |
| Development Tech | Abgenix XenoMouse |
| Previous Name | NA |
| Gm Offical Target Name | IL17A |
| Package |
Previous slide
Next slide
